FandG Annuities and Life, Inc. 7.950% Senior Notes due 2053 (FGN)
Live price chart, market sentiment, and community perspectives for FandG Annuities and Life, Inc. 7.950% Senior Notes due 2053 (NYSE: FGN).
Live price chart, market sentiment, and community perspectives for FandG Annuities and Life, Inc. 7.950% Senior Notes due 2053 (NYSE: FGN).
Dealer gamma exposure on FGN creates elevated volatility near the current strike cluster. Not adding exposure until after the backlog data clears.
On our credit desk, we noticed that FandG Annuities and Life's 7.950% Senior Notes due 2053 (FGN) traded completely unchanged during the Q2 2026 earnings release, even as the underlying equity took a hit. The market is evidently separating the fixed-income risk profile from the equity-side GAAP loss of $0.62 per share, which was heavily distorted by $144 million in unfavorable mark-to-market effects.
Reviewing the Q1 2026 metrics for FGN, the EPS came in at $0.82, missing consensus estimates by nearly 21%. Despite this miss on the scoreboard, the notes and underlying stock actually ticked up slightly by 0.44 points. This indicates that fixed-income and equity investors might have fully discounted the earnings shortfall or were anchored on longer-term capital strength.
As a hedge fund portfolio manager tracking spread and fee income stories, I am watching the recent margin squeeze closely. FandG reported a Q2 2026 net loss of $81 million, with adjusted net earnings declining 17% to $85 million due to softer alternative-investment returns. While assets under management hit a record $74.7 billion, gross sales fell 34% as management pulled back on opportunistic volumes.
When modeling this credit, analysts need to separate out the non-cash mark-to-market fluctuations from core operating performance. The Q2 GAAP loss was primarily driven by $144 million in unfavorable mark-to-market items and $22 million in other unfavorable items, all of which are explicitly excluded from adjusted net earnings. Understanding this accounting delta is crucial for assessing long-term solvency.
From a risk management standpoint, the key takeaway from the latest reporting cycle is that FandG's revenue rose 4% to $1.421 billion in Q2 2026, but total benefits and expenses surged 16%. This expansion in expenses paired with product-margin pressure creates a temporary earnings air pocket that justifies keeping a close eye on interest coverage ratios for the 2053 senior notes.
Explore plasma cleansing, somatic organ swaps, and BCI.